First-line nivolumab plus chemotherapy versus chemotherapy alone …
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00797-2/abstract
WEBJun 5, 2021 · First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial - The Lancet. Articles | Volume 398, ISSUE 10294, P27-40, July 03, 2021.
DA: 74 PA: 60 MOZ Rank: 90